about
Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in TanzaniaConcentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis.Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIVIVGTT glucose minimal model covariate selection by nonlinear mixed-effects approachIntegration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics.The pharmacokinetics of nevirapine when given with isoniazid in South African HIV-infected individuals.Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection.The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications.Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines.Model-based approach to dose optimization of lopinavir/ritonavir when co-administered with rifampicin.Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic ExtractionTreatment Failure, Drug Resistance, and CD4 T-Cell Count Decline Among Postpartum Women on Antiretroviral Therapy in South AfricaA time-to-event pharmacodynamic model describing treatment response in patients with pulmonary tuberculosis using days to positivity in automated liquid mycobacterial culturePopulation Pharmacokinetics of Rifampin in Pregnant Women with Tuberculosis and HIV Coinfection in Soweto, South Africa.Assessment of beta-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests.The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African childrenPopulation pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children.HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients.Model-based evaluation of the pharmacokinetic differences between adults and children for lopinavir and ritonavir in combination with rifampicinCharacterizing multisegment foot kinematics during gait in diabetic foot patients.Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children.Plasma Efavirenz Exposure, Sex, and Age Predict Virological Response in HIV-Infected African Children.Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients.Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended dosesThe disposition index: from individual to population approach.Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis.Pharmacokinetics of Sulfadoxine and Pyrimethamine for Intermittent Preventive Treatment of Malaria During Pregnancy and After Delivery.Determinants of virological outcome and adverse events in African children treated with paediatric nevirapine fixed-dose-combination tablets.Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB.Optimization of the strength of the efavirenz/lamivudine/abacavir fixed-dose combination for paediatric patients.Antimalarial and anticancer activities of artemisinin-quinoline hybrid-dimers and pharmacokinetic properties in mice.Antimalarial Pyrido[1,2-a]benzimidazoles: Lead Optimization, Parasite Life Cycle Stage Profile, Mechanistic Evaluation, Killing Kinetics, and in Vivo Oral Efficacy in a Mouse Model.Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants.Effect of mid-dose efavirenz concentrations and CYP2B6 genotype on viral suppression in patients on first-line antiretroviral therapy.Erratum for Chirehwa et al., Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction.In vivo efficacy and bioavailability of lumefantrine: Evaluating the application of Pheroid technology.Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine.Pharmacokinetic evaluation of lisinopril-tryptophan, a novel C-domain ACE inhibitor.Pharmacometrics: opportunity for reducing disease burden in the developing world: the case of Africa.Nonlinear mixed effects to improve glucose minimal model parameter estimation: a simulation study in intensive and sparse sampling.
P50
Q28550488-E20D6039-8E25-430D-9293-7960D35DFB59Q33621748-6BE75457-BE83-4A32-B2EC-27B6FB4D9F8AQ33797999-8205C2D8-60C1-442E-B8F0-DAE68382CAB7Q33840340-C7E94C03-BEB2-42C3-A7DE-02AD9D62A0D6Q34149022-D301DC20-461D-4BA2-96CD-51E192A8947DQ34251459-8720ACE0-1D33-4EC5-99F2-1B064166CEE0Q35102702-6D3E55DE-1000-4625-BCEB-A58921FD3B46Q35191432-68D795CB-BD95-4DBC-949A-0148561D6094Q36018761-300B01FD-E8DA-4106-90CB-9B09174D8990Q36111218-6FB1ADBF-25D9-4486-9042-535690FC25F3Q36438900-387383B5-08F9-4124-B5B2-80D99D20810CQ36463979-7771B2B4-C45B-42D1-9EA4-58C3C71F677FQ36558478-4ED2EE11-85EC-4E03-A72E-EE878F598CF1Q36644907-BA06ED8E-2F55-465F-98B8-C35D2B5F5F4CQ36753104-B31EC695-7840-4953-B52C-9F2942CB75C6Q37030715-367F7101-EA54-4EDD-BEC9-F35B26DBA7FAQ37094229-E8F557D2-6D30-437A-A313-1554C0F6E8A3Q37287701-A548BBBB-8A0B-4873-848C-E770AB6F7444Q37369323-60CAB538-EEC4-4F7A-A86D-ED07A2B81934Q37415900-BA6ED08A-117E-4C12-B62F-280DA45C4E6FQ37509532-94F2CCDF-31F2-48AF-902F-1C72DB88A78CQ37519804-8FCD7F2F-58E0-44A0-9E99-1B8107C8CF21Q37544479-FB1C2FCB-7048-4519-9241-5BA3945D5503Q37688266-961C5767-01BB-4652-BC11-8B339CCD0449Q38016319-AF9CA521-B221-4F7D-BDE5-50E426D869C5Q38729024-72A59754-EBEF-471F-91C9-863BE50B03D5Q38734572-3B877D1D-0052-48FA-8365-00F8C0F7B7C7Q38851687-DEA70B76-DECA-4BE0-80E0-3FB981A35014Q38973113-2C10AC05-BE8B-44B7-8283-F7BE596AF4AEQ39231462-53D57FEA-C101-4B44-8744-080C092928CEQ39258808-0A414FF2-3DFD-4388-9685-7B4595C843A3Q39466796-8B95D1CE-092C-4093-AB63-CB0ECA6AA539Q40246904-9E92AFEA-4CDA-4D3C-99DE-9B5D78FD9806Q40664342-734AB03E-5191-4F9A-BA9F-16BEE7D22BA1Q41287099-3EF1A675-8AAB-4342-85D9-43BC555438D0Q41916570-EE05BA3B-654A-4BF3-BE42-8CDCA77748DEQ41962727-C62AB50D-E450-41EF-9311-A9CB66B90F2FQ42227359-0C80D862-1DDE-4DCA-A7EB-A1BE027CBB60Q42249532-9A1A6070-D5C1-4742-94C1-1506DC197814Q45164902-DA25B9C7-0196-4A4B-85B3-C117AFAB7513
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Paolo Denti
@ast
Paolo Denti
@en
Paolo Denti
@es
Paolo Denti
@nl
Paolo Denti
@sl
type
label
Paolo Denti
@ast
Paolo Denti
@en
Paolo Denti
@es
Paolo Denti
@nl
Paolo Denti
@sl
prefLabel
Paolo Denti
@ast
Paolo Denti
@en
Paolo Denti
@es
Paolo Denti
@nl
Paolo Denti
@sl
P214
P1053
H-6393-2015
P106
P1153
49861227300
P21
P214
P31
P3829
P396
IT\ICCU\CFIV\270379
P496
0000-0001-7494-079X
P569
1981-01-01T00:00:00Z
P735
P7859
viaf-307343119